StoneX Reiterates Buy Rating on Kamada Ltd. (KMDA) on Increased Demand for Anti-Rabies Treatment

September 18, 2026 9:20 AM EDT Send to a Friend
StoneX analyst Robert Wasserman reiterated a Buy rating and $15.00 price target on Kamada Ltd. (NASDAQ: KMDA).The analyst commented, "A ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login